IG Dwell December 2: The Weight of Wegovy

MedPage This day spoke with experts one day of an Instagram Dwell 2 years within the past in regards to the rising buzz round GLP-1 receptor agonists and their role in transforming diabetes and weight problems care. Since then, the exhaust of medicines love semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has severely change even extra frequent as the treatment’ listing of proven and capacity advantages develop.

Current be taught has advised that GLP-1 agonists might possibly presumably furthermore provide advantages for of us with alcohol, opioid, and tobacco exhaust disorders, and shown associations between exhaust of the drug class and a decrease threat of Alzheimer’s illness. Compare have furthermore tied GLP-1 treatment to reduced threat of COVID-19 mortality, weight problems-connected cancers, and glaucoma in obvious patients.

On the opposite hand, the treatment have their limits — equivalent to weight-loss plateaus and weight accept after stopping treatment — and as their recognition grows, questions remain about perioperative and long-term security, compounded drug dangers, along with equitable web entry to and affordability.

In an upcoming Instagram Dwell, MedPage This day will revisit the conversation to chat about how the landscape has changed and what clinicians settle on to understand about these modern treatment — join us!

Featuring:

Jeremy Faust, MD (moderator) editor-in-chief at MedPage This day (@jeremysamuelfaust)

Karl Nadolsky, DO, scientific endocrinologist and weight problems specialist at Holland Scientific institution (@drkarlnadolsky)

Fatima Cody Stanford, MD, MPH, MPA, MBA, affiliate professor of treatment and pediatrics at Massachusetts Total Scientific institution and Harvard Scientific College (@askdrfatima)

How attain I join? Apply @medpage on Instagram!

When is the tournament? Tune in Monday, December 2 at 2 p.m. ET

Can I submit questions? Optimistic, we motivate questions! Post your questions prior to the tournament by commenting below.

Associated articles:

Ozempic Linked With Lower Risk of Alzheimer’s Prognosis

Right here is How Compounders Manufacture Trendy Weight-Loss Medications

Over 50% of U.S. Adults Qualify for Ozempic, Wegovy

FDA Adds New Warning to GLP-1 Medications

GLP-1 Medications Might Abet Americans With Alcohol Utilize Dysfunction

GLP-1 Agent Might Succor Opioid Utilize Dysfunction Profit

The Recordsdata Are Optimistic: Patients Procure Weight After Stopping GLP-1 Medications

GLP-1 Agonists Might Offer Protection Towards Glaucoma in Form 2 Diabetes

Americans Without Diabetes Manufacture Up Rising Section of GLP-1 Customers

Can a GLP-1 Agonist Toughen Parkinson’s Signs?

GLP-1 Medications Linked to Lower Colorectal Most cancers Risk for Diabetes Patients

Wegovy Protects Towards Lethal COVID Instances

How On the total Attain Scientific doctors Utilize New Weight-Loss Medications in Youth?